U.S. Markets closed

Moving Average Crossover Alert: EPAM Systems

Zacks Equity Research
Bouts of volatility and uncertainty have raised the appeal of leveraged and inverse leveraged ETFs in March for huge gains in a short span.

EPAM Systems, Inc. EPAM is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for EPAM broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.

This has already started to take place, as the stock has moved higher by 11.2% in the past four weeks. Plus, the company currently has a Zacks Rank #1 (Strong Buy) suggesting that now could definitely be the time for this breakout candidate.

More bullishness may especially be the case when investors consider what has been happening for EPAM on the earnings estimate revision front lately. No estimate has gone lower in the past two months, compared to 1 higher, while the consensus estimate has also moved higher too.

So given this move in estimates, and the positive technical factors, investors may want to watch this breakout candidate closely for more gains in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
EPAM Systems, Inc. (EPAM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research